Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK.
J Cardiovasc Magn Reson. 2014 May 27;16(1):38. doi: 10.1186/1532-429X-16-38.
Microvascular obstruction (MVO) describes suboptimal tissue perfusion despite restoration of infarct-related artery flow. There are scarce data on Infarct Size (IS) and MVO in relation to the mode and timing of reperfusion. We sought to characterise the prevalence and extent of microvascular injury and IS using Cardiovascular magnetic resonance (CMR), in relation to the mode of reperfusion following acute ST-Elevation Myocardial Infarction (STEMI).
CMR infarct characteristics were measured in 94 STEMI patients (age 61.0 ± 13.1 years) at 1.5 T. Seventy-three received reperfusion therapy: primary percutaneous coronary-intervention (PPCI, n = 47); thrombolysis (n = 12); rescue PCI (R-PCI, n = 8), late PCI (n = 6). Twenty-one patients presented late (>12 hours) and did not receive reperfusion therapy.
IS was smaller in PPCI (19.8 ± 13.2% of LV mass) and thrombolysis (15.2 ± 10.1%) groups compared to patients in the late PCI (40.0 ± 15.6%) and R-PCI (34.2 ± 18.9%) groups, p <0.001. The prevalence of MVO was similar across all groups and was seen at least as frequently in the non-reperfused group (15/21, [76%] v 33/59, [56%], p = 0.21) and to a similar magnitude (1.3 (0.0-2.8) v 0.4 [0.0-2.9]% LV mass, p = 0.36) compared to patients receiving early reperfusion therapy. In the 73 reperfused patients, time to reperfusion, ischaemia area at risk and TIMI grade post-PCI were the strongest independent predictors of IS and MVO.
In patients with acute STEMI, CMR-measured MVO is not exclusive to reperfusion therapy and is primarily related to ischaemic time. This finding has important implications for clinical trials that use CMR to assess the efficacy of therapies to reduce reperfusion injury in STEMI.
尽管梗死相关动脉血流已经恢复,但微血管阻塞(MVO)仍描述了组织灌注不佳的情况。关于再灌注方式和时间与梗塞大小(IS)和 MVO 的关系,数据很少。我们试图使用心血管磁共振(CMR)描述与急性 ST 段抬高型心肌梗死(STEMI)后再灌注模式相关的微血管损伤和 IS 的发生率和程度。
在 1.5 T 下测量 94 例 STEMI 患者(年龄 61.0±13.1 岁)的 CMR 梗死特征。73 例接受再灌注治疗:直接经皮冠状动脉介入治疗(PPCI,n=47);溶栓(n=12);补救性经皮冠状动脉介入治疗(R-PCI,n=8),延迟经皮冠状动脉介入治疗(n=6)。21 例患者发病时间较晚(>12 小时)且未接受再灌注治疗。
与延迟 PCI(40.0±15.6%)和 R-PCI(34.2±18.9%)组相比,PPCI(19.8±13.2%)和溶栓(15.2±10.1%)组的 IS 更小,p<0.001。所有组的 MVO 发生率相似,在未再灌注组中也至少同样常见(15/21,[76%]比 59/59,[56%],p=0.21),且程度相似(1.3(0.0-2.8)比 0.4(0.0-2.9)%LV 质量,p=0.36)与接受早期再灌注治疗的患者相比。在 73 例再灌注患者中,再灌注时间、缺血危险区和 PCI 后 TIMI 分级是 IS 和 MVO 的最强独立预测因素。
在急性 STEMI 患者中,CMR 测量的 MVO 不仅与再灌注治疗有关,而且主要与缺血时间有关。这一发现对临床试验具有重要意义,临床试验使用 CMR 评估治疗 STEMI 再灌注损伤的疗效。